Last updated: September 10, 2026
LOQTORZI, the brand name for toripalimab-tpzi, is an anti-PD-1 monoclonal antibody developed by China-based Shanghai Junshi Biosciences and commercialized in the United States by Coherus BioSciences. The FDA approved LOQTORZI in October 2023 for metastatic or recurrent locally advanced nasopharyngeal carcinoma, initially in combination with gemcitabine and cisplatin and then as maintenance monotherapy.
The product has a differentiated regulatory position in a rare U.S. indication, but its commercial ceiling is constrained by the small nasopharyngeal-cancer market, intense PD-1 competition, dependence on oncology-center adoption, and Coherus’ need to fund commercial infrastructure. Near-term value depends primarily on U.S. market penetration and additional indications rather than on the approved indication alone.
What is LOQTORZI and who commercializes it?
LOQTORZI is toripalimab-tpzi, a programmed death receptor-1, or PD-1, inhibitor. It blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, enabling T-cell activity against tumor cells.
| Item |
Detail |
| Brand |
LOQTORZI |
| Active ingredient |
Toripalimab-tpzi |
| Drug class |
Anti-PD-1 monoclonal antibody |
| U.S. sponsor |
Coherus BioSciences, Inc. |
| Original developer |
Shanghai Junshi Biosciences Co., Ltd. |
| U.S. approval date |
October 27, 2023 |
| Approved disease |
Recurrent, unresectable, or metastatic nasopharyngeal carcinoma |
| Initial combination |
Gemcitabine and cisplatin |
| Maintenance treatment |
LOQTORZI monotherapy |
| FDA pathway |
Biologics license application |
| U.S. launch |
Late 2023 |
The pivotal basis for approval was the JUPITER-02 study, a randomized Phase 3 trial conducted primarily in China. The trial evaluated toripalimab plus gemcitabine and cisplatin against chemotherapy alone in recurrent or metastatic nasopharyngeal carcinoma. The FDA also relied on the POLARIS-02 study for monotherapy activity in previously treated disease. (U.S. Food and Drug Administration, 2023a, 2023b)
What is the FDA regulatory status of LOQTORZI?
The FDA granted LOQTORZI regular approval for first-line treatment in combination with chemotherapy and accelerated approval for monotherapy after platinum-containing chemotherapy. The accelerated-approval component requires confirmatory evidence.
The FDA label includes a boxed warning for immune-mediated adverse reactions. Important risks include pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic reactions, and infusion-related reactions. These risks are consistent with the broader PD-1 inhibitor class and can affect treatment selection, monitoring, and payer utilization controls.
The FDA approval gave Coherus access to a U.S. product with no direct domestic anti-PD-1 generic pathway. Commercial performance therefore depends on clinical adoption rather than immediate substitution economics.
When does LOQTORZI lose biologic exclusivity?
LOQTORZI received 12 years of reference-product exclusivity under the Biologics Price Competition and Innovation Act. Based on the FDA approval date of October 27, 2023, the reference-product exclusivity period is expected to run through approximately October 27, 2035, subject to statutory calculations and any pediatric extension.
| Protection type |
Expected timing |
Commercial effect |
| FDA reference-product exclusivity |
Approximately October 2035 |
Prevents FDA approval of a biosimilar application before the exclusivity period ends |
| Patent protection |
Depends on individual patent terms |
May extend beyond or expire before biologic exclusivity |
| Pediatric exclusivity |
Not identified in the core approval record |
Could add six months if awarded |
| Market exclusivity in nasopharyngeal carcinoma |
Not indication-specific |
Competing PD-1 products remain available |
Biologic exclusivity does not prevent competing antibodies from entering the same market through their own biologics license applications. It primarily delays biosimilar approval relying on LOQTORZI’s reference-product data.
What patents protect LOQTORZI?
The commercial protection for LOQTORZI is expected to include antibody composition, binding characteristics, pharmaceutical formulations, manufacturing processes, and treatment methods. Junshi’s underlying intellectual-property position is central because Coherus commercializes the product under an exclusive license rather than owning the original molecule outright.
Unlike small-molecule drugs, LOQTORZI does not use the FDA Orange Book as its principal patent listing mechanism. Biologic patent and exclusivity analysis requires review of the Purple Book, FDA disclosures, USPTO records, patent assignments, and applicable licensing agreements.
The public commercial record does not establish a single, definitive Orange Book-style list of all enforceable LOQTORZI patents. The relevant risk profile is therefore more complex than a small-molecule product with one or two clearly listed composition-of-matter patents.
Which formulation and method-of-use patents could matter?
Potentially relevant patent categories include:
- Toripalimab antibody sequence and antigen-binding claims.
- Antibody variants with defined affinity or functional activity.
- Combination treatment with gemcitabine and cisplatin.
- Use in recurrent or metastatic nasopharyngeal carcinoma.
- Dosing schedules and maintenance monotherapy.
- Stable liquid or injectable formulations.
- Cell-line, purification, and manufacturing methods.
Method-of-use patents may have commercial importance if Coherus expands into additional tumor types. They generally provide narrower protection than a valid composition-of-matter claim because competitors may attempt alternative indications, dosing regimens, or clinical-label strategies.
How strong is the LOQTORZI patent estate?
LOQTORZI has a stronger regulatory exclusivity profile than an immediate patent-led profile. The 12-year U.S. reference-product exclusivity period provides a substantial barrier to biosimilar reliance, but it does not create a monopoly over PD-1 therapy.
Patent strength depends on four factors:
- Whether Junshi’s antibody claims survive validity challenges.
- Whether U.S. patents cover the marketed antibody rather than only related candidates.
- Whether formulation and manufacturing claims are independently enforceable.
- Whether Coherus and Junshi maintain broad geographic coverage outside the United States.
The principal weakness is class substitution. Even if LOQTORZI patents remain enforceable, Keytruda, Opdivo, Libtayo, Tevimbra, and other immunotherapies can compete without infringing LOQTORZI-specific patents.
What is the commercial market for LOQTORZI?
Nasopharyngeal carcinoma is geographically concentrated. The highest disease burden is in southern China, Southeast Asia, and selected North African regions. U.S. incidence is comparatively low. The U.S. label therefore creates a focused specialty-oncology opportunity rather than a broad immuno-oncology franchise.
Commercial drivers include:
- Treatment concentration at academic and high-volume cancer centers.
- Physician familiarity with PD-1 inhibitors.
- Guideline inclusion and payer coverage.
- Use of cisplatin and gemcitabine in the first-line setting.
- Adoption in patients who relapse after platinum therapy.
- Expansion into other solid tumors.
Commercial constraints include:
- Small U.S. nasopharyngeal-carcinoma population.
- Existing use of established PD-1 and PD-L1 inhibitors.
- Treatment toxicity and chemotherapy burden.
- Hospital formulary competition.
- Coherus’ smaller oncology infrastructure compared with Merck and Bristol Myers Squibb.
- Potential pressure from lower-cost competitive immunotherapies.
The approved combination regimen is clinically relevant but operationally demanding. Patients receive an antibody alongside cytotoxic chemotherapy, creating infusion, monitoring, and adverse-event management requirements.
What is the financial trajectory for LOQTORZI?
LOQTORZI entered the U.S. market in late 2023, so its revenue trajectory remains launch-stage rather than mature. Coherus has identified LOQTORZI as a growth product intended to offset pressure on its biosimilar and ophthalmology franchises.
The most defensible financial interpretation is:
| Period |
Financial stage |
Main commercial issue |
| 2023 |
Initial launch |
Limited contribution because the product launched late in the year |
| 2024 |
Early market buildout |
Formulary access, account activation, and diagnosis-to-treatment conversion |
| 2025-2026 |
Scale-up phase |
Repeat treatment, guideline penetration, and indication expansion |
| 2027 onward |
Franchise test |
Ability to broaden use beyond nasopharyngeal carcinoma |
Coherus’ corporate filings and earnings disclosures should be read carefully because reported revenue can include product sales, licensing income, collaboration revenue, and other categories. LOQTORZI-specific sales may not always be presented with the same granularity across reporting periods. The product’s financial contribution is therefore better assessed through quarterly product-revenue disclosures, prescription trends, treatment-center adoption, gross-to-net discounts, and commercial investment.
The principal financial risk is that LOQTORZI remains a single-indication product. Under that scenario, sales could reach a meaningful specialty-oncology level but would be unlikely to become a blockbuster comparable with Keytruda or Opdivo. The upside case requires successful expansion into additional cancers, particularly tumors where toripalimab has supportive Phase 3 data and a commercially differentiated position.
Which companies are challenging LOQTORZI?
No Paragraph IV challenge is expected to apply in the ordinary small-molecule sense because LOQTORZI is a biologic and is not protected through the standard Orange Book abbreviated new drug application framework.
The competitive set includes:
| Competitor |
Company |
Competitive relevance |
| Keytruda |
Merck |
Dominant PD-1 franchise with broad indications and strong payer presence |
| Opdivo |
Bristol Myers Squibb |
Established PD-1 product with extensive oncology use |
| Libtayo |
Regeneron and Sanofi |
Competes in multiple solid tumors |
| Tevimbra |
BeiGene |
Directly relevant Chinese-developed PD-1 competitor with U.S. approval |
| Imfinzi |
AstraZeneca |
PD-L1 competitor in head and neck and other cancers |
| Bavencio |
Pfizer and Merck KGaA |
PD-L1 option in selected oncology settings |
Tevimbra is the closest commercial comparator because it is also a China-origin immunotherapy pursuing U.S. oncology expansion. Keytruda and Opdivo remain the strongest competitive threats because of their installed physician base, broad labels, and extensive clinical evidence.
What licensing deal supports LOQTORZI?
Coherus licensed North American rights to toripalimab from Junshi Biosciences. The transaction gave Coherus responsibility for U.S. development, regulatory approval, and commercialization while Junshi retained rights in other territories.
The agreement aligns incentives but also creates economic leakage through royalties, milestone obligations, and potential profit-sharing. Coherus gains access to a late-stage biologic without bearing the full cost of original discovery. Junshi gains a U.S. commercialization partner with an established specialty-pharmaceutical platform.
For financial modeling, analysts should separate:
- Product gross sales.
- Net sales after rebates and discounts.
- Royalties payable to Junshi.
- Sales and marketing expense.
- Regulatory and post-approval study costs.
- Milestone payments.
- Potential manufacturing-transfer costs.
What generic and biosimilar entry risks exist?
The near-term U.S. substitution risk is low because reference-product exclusivity is expected to extend into 2035. The more immediate threat is therapeutic competition rather than biosimilar entry.
Potential long-term entry scenarios include:
- A biosimilar application filed after the reference-product exclusivity period.
- A competing anti-PD-1 antibody gaining a superior label.
- Price competition from other China-origin immunotherapies.
- Physician migration to products with simpler dosing or broader combination data.
- Contracting pressure from integrated delivery networks and oncology purchasing groups.
Manufacturing presents a secondary barrier. Monoclonal antibodies require validated cell culture, purification, analytical comparability, sterility controls, and supply-chain reliability. These requirements increase the cost and technical complexity of biosimilar development, but they do not prevent eventual competition.
What is the geographic opportunity for LOQTORZI?
The United States is the most important near-term commercial market under the Coherus partnership. China remains strategically important to Junshi because nasopharyngeal carcinoma is more prevalent there and the company has local commercial infrastructure.
The broader opportunity extends to:
- China and Hong Kong.
- Southeast Asia.
- Taiwan.
- Selected Middle Eastern and North African markets.
- Other regions with elevated Epstein-Barr virus-associated nasopharyngeal carcinoma incidence.
Geographic expansion depends on local approvals, pricing, reimbursement, manufacturing capacity, and the allocation of rights under Junshi’s licensing arrangements.
Key Takeaways
- LOQTORZI is toripalimab-tpzi, an anti-PD-1 biologic commercialized in the United States by Coherus and developed by Junshi.
- The FDA approved it in October 2023 for recurrent, locally advanced, or metastatic nasopharyngeal carcinoma.
- U.S. reference-product exclusivity is expected to protect the product from biosimilar reliance until approximately October 2035.
- The product is not an Orange Book-listed small molecule; biologic exclusivity and patent analysis require Purple Book, USPTO, FDA, and licensing-record review.
- The approved indication is commercially focused and geographically concentrated.
- Keytruda, Opdivo, Libtayo, and Tevimbra create substantial therapeutic competition.
- Financial upside depends on indication expansion, not only penetration of the U.S. nasopharyngeal-carcinoma market.
- No conventional Paragraph IV pathway applies to LOQTORZI.
- The main near-term risk is class competition, while biosimilar risk is primarily a post-2035 issue.
FAQs
Is LOQTORZI a biosimilar?
No. LOQTORZI is an original biologic product containing toripalimab-tpzi. It is not a biosimilar to Keytruda, Opdivo, or another PD-1 inhibitor.
Does LOQTORZI have an Orange Book patent listing?
No conventional Orange Book listing is expected because LOQTORZI is a biologic. Relevant protection is assessed through biologic exclusivity, patent records, FDA materials, and licensing documents.
Can LOQTORZI compete directly with Keytruda?
Yes. Both are PD-1 inhibitors, but their labels, clinical evidence, physician adoption, and reimbursement positions differ. Keytruda has a substantially broader commercial franchise.
What would increase LOQTORZI sales most?
An FDA label expansion into additional solid tumors would have the greatest potential effect. Improved guideline positioning, payer access, and evidence supporting use in earlier treatment lines would also support growth.
Is LOQTORZI exposed to near-term biosimilar erosion?
No material near-term biosimilar erosion is expected under the 12-year U.S. reference-product exclusivity framework. Competitive erosion from other branded immunotherapies is the more immediate risk.
References
-
Coherus BioSciences, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
-
Junshi Biosciences. (2023). Toripalimab development and commercialization information. Shanghai Junshi Biosciences Co., Ltd.
-
U.S. Food and Drug Administration. (2023a). FDA approves toripalimab-tpzi with chemotherapy for metastatic or recurrent locally advanced nasopharyngeal carcinoma. Center for Drug Evaluation and Research.
-
U.S. Food and Drug Administration. (2023b). LOQTORZI prescribing information. Center for Drug Evaluation and Research.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. Center for Drug Evaluation and Research.
-
U.S. Securities and Exchange Commission. (2024). Coherus BioSciences corporate filings and quarterly financial disclosures.
